Latest posts
-
When Early Reports Leave Key Details Open
The first account of an unfolding event often answers only part of the basic questions. Knowing which details are confirmed—and which remain open—makes the next update easier to read.
-
Fitness became an addiction that left me anxious and sleep deprived
Wayne Davies was left “constantly worrying” about race times, comparing himself to other runners on social media.
-
Where Are the Biggest Opportunities in Women’s Cardiovascular Health?
MedTech Conference panelists cited inflammation research, listening to women, clinical trial representation and investment as priorities for women’s cardiovascular health. The post Where Are the Biggest Opportunities in Women’s Cardiovascular Health? appeared first on MedCity News.
-
GP says she was forced out of job after raising concerns about gender treatment
The doctor says she faced a brutal investigation after she passed on complaints brought to her by other doctors.
-
STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
-
STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclear
The American Diabetes Association has issued two explanations, two reviews and an apology over its June convention. A Friday report adds new twists.
-
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
Where should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?
-
STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds
Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.
-
Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill
Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 receptor to treat inflammatory bowel disease. It could compete against Johnson & Johnson’s Icotyde, an oral peptide that blocks the same target and is also in development for IBD. The post Gilead to Pay $1.3B for Oral…
-
STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.